How can we target pulmonary inflammation in cystic fibrosis?

Open Respiratory Medicine Journal

Volumn 4, Issue , 2010, Pages 18-19

  Greene, Catherine M ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIBIOTIC AGENT; CATHEPSIN; CERAMIDE; CHLORIDE ION; GLYCYLPROLINE; HIGH MOBILITY GROUP B1 PROTEIN; LEUKOCYTE ELASTASE; MATRIX METALLOPROTEINASE; PROLYLGLYCYLPROLINE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SPHINGOMYELIN PHOSPHODIESTERASE; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; BACTERIAL INFECTION; CHLORIDE CONDUCTANCE; CYSTIC FIBROSIS; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; EDITORIAL; HUMAN; INFECTION SENSITIVITY; LIPID BLOOD LEVEL; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL;

EID: 77953366200     PISSN: None     EISSN: 18743064     Source Type: Journal    
DOI: 10.2174/1874306401004020018     Document Type: Editorial

References (6)

1. Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira-Munding CC. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008; 14(4): 382-91.
2. Gaggar A, Jackson PL, Noerager BD, O'Reilly PJ, McQuaid DB, Rowe SM. A novel proteolytic cascade generates an extracellular matrix-derivedchemoattractant in chronic neutrophilic inflammation. J Immunol 2008; 180(8): 5662-9.
3. Rowe SM, Jackson PL, Liu G, et al. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 2008; 178(8): 822-31.
4. Taggart CC, Greene CM, McElvaney NG, O'Neill S. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem 2002; 277(37): 33648-53.
5. Greene CM, McElvaney NG, O'Neill SJ, Taggart CC. Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun 2004; 72(6): 3684-7.
6. Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med 2005; 202(12): 1659-68.